Valneva SE (EPA:VLA)
France
· Delayed Price · Currency is EUR | Market Cap | 648.45M |
| Revenue (ttm) | 179.91M |
| Net Income (ttm) | -102.16M |
| Shares Out | 171.73M |
| EPS (ttm) | -0.61 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 570,345 |
| Average Volume | 956,359 |
| Open | 3.720 |
| Previous Close | 3.776 |
| Day's Range | 3.710 - 3.858 |
| 52-Week Range | 1.726 - 5.415 |
| Beta | 1.28 |
| RSI | 46.51 |
| Earnings Date | Nov 20, 2025 |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]
Financial Performance
In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.
Financial StatementsNews
Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings
Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15.
Valneva Posts Positive Lyme Vaccine Booster Results — Pfizer Targeting 2026 Regulatory Filings
Valneva SE (NASDAQ: VALN) shared final immunogenicity and safety data on Wednesday from the Phase 2 study, VLA15-221, of the Lyme disease vaccine candidate, VLA15 . Lyme disease is a bacterial infect...
Valneva to Further Consolidate its Operations in France
Saint- Herblain (France), November 26 , 202 5 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced a strategic initiative to optimize its organizational footprint in France as part ...
Valneva Shares Rise on Positive Data from Lyme Disease Vaccine Study
Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial.
Valneva's Lyme Vaccine VLA15 Shows Strong Phase 2 Booster Results With Favorable Safety
(RTTNews) - Valneva SE (VALN) announced positive final immunogenicity and safety data from its Phase 2 study, VLA15-221, evaluating the Lyme disease vaccine candidate VLA15. The study results demonstr...
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease...
Valneva SE (INRLF) Nine Months 2025 Earnings Call Highlights: Revenue Growth Amid Operational ...
Valneva SE (INRLF) Nine Months 2025 Earnings Call Highlights: Revenue Growth Amid Operational Challenges
Valneva SE (VALN) Q3 2025 Earnings Call Transcript
Nine Months 2025 Valneva SE Earnings Call Transcript
Nine Months 2025 Valneva SE Earnings Call Transcript
Valneva SE 2025 Q3 - Results - Earnings Call Presentation
2025-11-20. The following slide deck was published by Valneva SE in conjunction with their 2025 Q3 earnings call.
Valneva SE reports Q3 results
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
Saint-Herblain (France), November 20, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the first nine months of the...
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Immune response successfully improved with second generation vaccine candidate Saint-Herblain (France), November 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, ...
Valneva to Present and Hold Investor Meetings at Upcoming U.S. and European Healthcare Conferences
Saint- Herblain (France), October 27 , 202 5 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
NEW YORK , Oct. 18, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
NEW YORK , Oct. 13, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
NEW YORK , Oct. 8, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact Da...
Valneva SE (VALN) Lowers 2025 Sales Forecast Amid Vaccine Setback
Valneva SE (VALN) Lowers 2025 Sales Forecast Amid Vaccine Setback
Valneva lowers 2025 financial outlook due to loss of Ixchiq vaccine marketing
Valneva cuts 2025 sales and revenue outlook after FDA revokes chikungunya vaccine. Read more here.
Valneva Strengthens Financial Position by Refinancing Debt with Pharmakon Advisors and Provides Business Updates
Saint-Herblain (France), October 6, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has entered into a debt facility for up to $500 million ...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
NEW YORK , Oct. 3, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN). Such investors are advised to contact D...
Valneva Reports Strong Four-Year Antibody Persistence For Chikungunya Vaccine IXCHIQ
(RTTNews) - Valneva SE (VALN) announced positive four-year antibody persistence data following a single-dose vaccination with its chikungunya vaccine, IXCHIQ. The results demonstrate robust and long-l...
Valneva Reports 95% Seroresponse Four Years After Single Shot of Chikungunya Vaccine IXCHIQ®
Saint-Herblain (France), September 30, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive antibody persistence data four years after vaccinatio...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
NEW YORK , Sept. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ: VALN).
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN
NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to con...